Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.300
+0.050 (1.18%)
Aug 17, 2026, 11:53 AM EDT - Market open

Aquestive Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Aquestive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.22. The average 1-year stock price forecast is 114.42% higher than the current stock price, while the lowest is $6.00 (+39.53%) and the highest is $11 (+155.81%).

Price Target: $9.22 (+114.42%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$6.00$9.22$10$11
Change+39.53%+114.42%+132.56%+155.81%

Analyst Ratings

The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Aug '26
Strong Buy777777
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total999999

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
LifeSci Capital
LifeSci Capital
Buy
Reiterates
$10
BuyReiterates$10+132.56%Aug 13, 2026
Lake Street
Lake Street
Buy
Maintains
$6
BuyMaintains$6+39.53%Aug 10, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$11
BuyMaintains$11+155.81%Jun 26, 2026
Chardan Capital
Chardan Capital
Buy
Reiterates
$8
BuyReiterates$8+86.05%Jun 25, 2026
Leerink Partners
Leerink Partners
Buy
Reiterates
$9
BuyReiterates$9+109.30%May 15, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
50.00M
from 44.55M
Increased by 12.25%
Revenue Next Year
68.87M
from 50.00M
Increased by 37.74%
EPS This Year
-0.45
from -0.59
EPS Next Year
-0.57
from -0.45
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
50.83M47.68M50.58M57.56M44.55M50.00M
Revenue Growth
10.87%-6.20%6.09%13.79%-22.61%12.25%
Gross Profit
35.84M28.29M29.75M39.69M25.99M35.10M
Gross Margin
70.51%59.34%58.82%68.95%58.35%70.20%
Operating Income
-34.68M-42.07M-15.10M-30.77M-71.05M-44.53M
Net Income
-70.54M-54.41M-7.87M-44.14M-83.78M-65.47M
EPS
-----0.59-0.45
Free Cash Flow
-28.10M-21.29M-16.22M-10.49M-29.24M-15.00M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High52.1M
Avg50.0M
Low49.2M

Revenue Growth

Revenue Growth202620272028
High
17.0%
Avg
12.2%
Low
10.4%

EPS Forecast

EPS202620272028
High-0.45
Avg-0.45
Low-0.45

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-